The effects of epinephrine on norepinephrine release in essential hypertension. 1985

M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi

The effects of endogenous epinephrine (E), released by glucagon injection, and exogenously infused E on plasma norepinephrine (NE) and cardiovascular responses before and after beta-blockade were studied in patients with essential hypertension and in age-matched normotensive controls. The resting plasma NE and E levels were significantly higher in the borderline hypertensive subjects (NE: 251 +/- 21 pg/ml [SEM], p less than 0.005; E: 57 +/- 5, p less than 0.05, n = 18) than in controls (NE: 129 +/- 12; E: 39 +/- 5, n = 18). An intravenous injection of glucagon (1.0 mg) induced a transient rise of both plasma catecholamine levels and blood pressure in every subject studied. Plasma E levels rose transiently and returned to the basal levels by 20 minutes after the injection, whereas plasma NE levels showed a more prolonged rise over 20 minutes. beta-Blockade with propranolol did not affect the plasma E response to glucagon, but inhibited the prolonged rise of plasma NE levels. An intravenous infusion of exogenous E (1.25-1.50 micrograms/min) for 30 minutes caused an apparent rise of both plasma NE levels and blood pressure, which lasted more than 60 minutes after stopping the E infusion. Propranolol did not affect the time course of plasma E but again inhibited the prolonged rise of both plasma NE levels and blood pressure. No significant differences could be observed in the cardiovascular or plasma NE responses to glucagon or to E infusion between normal and hypertensive subjects. These findings lend support to the view that plasma E can act physiologically as a sustained stimulator of presynaptic beta-adrenergic receptors, which leads to an enhanced NE release from peripheral sympathetic nerve terminals and a rise of blood pressure in humans.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D005260 Female Females

Related Publications

M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
August 1981, Clinical pharmacology and therapeutics,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
January 1984, Federation proceedings,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
December 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
November 1997, Hypertension (Dallas, Tex. : 1979),
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
January 2000, Journal of cardiovascular pharmacology,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
July 1993, The American journal of physiology,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
October 1988, The American journal of cardiology,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
December 2000, Journal of hypertension,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
May 1980, The Journal of clinical endocrinology and metabolism,
M Nezu, and Y Miura, and M Adachi, and M Adachi, and S Kimura, and S Toriyabe, and Y Ishizuka, and H Ohashi, and T Sugawara, and M Takahashi
January 1986, Hormone research,
Copied contents to your clipboard!